Trends Immunol. 2024 Nov 27:S1471-4906(24)00278-3. doi: 10.1016/j.it.2024.11.007. Online ahead of print.
ABSTRACT
In the battle against cancer, researchers are exploring the use of engineered bacteria as living medicines. Redenti and colleagues demonstrate that Escherichia coli Nissle 1917 (EcN) can be engineered to deliver cancer neoantigen payloads, stimulating antigen-specific CD4+ and CD8+ T cells and mediating antitumor immunity in preclinical models of colorectal cancer and melanoma.
PMID:39603891 | DOI:10.1016/j.it.2024.11.007